构建bug研讨会:使用微生物与宿主的相互作用和合成生物学工具来创建癌症疗法。

Vishnu Raman, Chinmay P Deshpande, Shradha Khanduja, Lars M Howell, Nele Van Dessel, Neil S Forbes
{"title":"构建bug研讨会:使用微生物与宿主的相互作用和合成生物学工具来创建癌症疗法。","authors":"Vishnu Raman,&nbsp;Chinmay P Deshpande,&nbsp;Shradha Khanduja,&nbsp;Lars M Howell,&nbsp;Nele Van Dessel,&nbsp;Neil S Forbes","doi":"10.1016/j.chom.2023.09.006","DOIUrl":null,"url":null,"abstract":"<p><p>Many systemically administered cancer therapies exhibit dose-limiting toxicities that reduce their effectiveness. To increase efficacy, bacterial delivery platforms have been developed that improve safety and prolong treatment. Bacteria are a unique class of therapy that selectively colonizes most solid tumors. As delivery vehicles, bacteria have been genetically modified to express a range of therapies that match multiple cancer indications. In this review, we describe a modular \"build-a-bug\" method that focuses on five design characteristics: bacterial strain (chassis), therapeutic compound, delivery method, immune-modulating features, and genetic control circuits. We emphasize how fundamental research into gut microbe pathogenesis has created safe bacterial therapies, some of which have entered clinical trials. The genomes of gut microbes are fertile grounds for discovery of components to improve delivery and modulate host immune responses. Future work coupling these delivery vehicles with insights from gut microbes could lead to the next generation of microbial cancer therapy.</p>","PeriodicalId":93926,"journal":{"name":"Cell host & microbe","volume":"31 10","pages":"1574-1592"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Build-a-bug workshop: Using microbial-host interactions and synthetic biology tools to create cancer therapies.\",\"authors\":\"Vishnu Raman,&nbsp;Chinmay P Deshpande,&nbsp;Shradha Khanduja,&nbsp;Lars M Howell,&nbsp;Nele Van Dessel,&nbsp;Neil S Forbes\",\"doi\":\"10.1016/j.chom.2023.09.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Many systemically administered cancer therapies exhibit dose-limiting toxicities that reduce their effectiveness. To increase efficacy, bacterial delivery platforms have been developed that improve safety and prolong treatment. Bacteria are a unique class of therapy that selectively colonizes most solid tumors. As delivery vehicles, bacteria have been genetically modified to express a range of therapies that match multiple cancer indications. In this review, we describe a modular \\\"build-a-bug\\\" method that focuses on five design characteristics: bacterial strain (chassis), therapeutic compound, delivery method, immune-modulating features, and genetic control circuits. We emphasize how fundamental research into gut microbe pathogenesis has created safe bacterial therapies, some of which have entered clinical trials. The genomes of gut microbes are fertile grounds for discovery of components to improve delivery and modulate host immune responses. Future work coupling these delivery vehicles with insights from gut microbes could lead to the next generation of microbial cancer therapy.</p>\",\"PeriodicalId\":93926,\"journal\":{\"name\":\"Cell host & microbe\",\"volume\":\"31 10\",\"pages\":\"1574-1592\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell host & microbe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chom.2023.09.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell host & microbe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.chom.2023.09.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

许多系统给药的癌症疗法表现出剂量限制性毒性,降低了其有效性。为了提高疗效,已经开发了细菌递送平台,以提高安全性并延长治疗时间。细菌是一种独特的治疗方法,可以选择性地定殖大多数实体瘤。作为递送载体,细菌经过基因改造,可以表达一系列与多种癌症适应症相匹配的疗法。在这篇综述中,我们描述了一种模块化的“构建bug”方法,该方法侧重于五个设计特征:菌株(底盘)、治疗化合物、递送方法、免疫调节特征和遗传控制电路。我们强调,对肠道微生物发病机制的基础研究如何创造出安全的细菌疗法,其中一些已经进入临床试验。肠道微生物的基因组是发现改善递送和调节宿主免疫反应的成分的肥沃土壤。未来的工作将这些递送载体与肠道微生物的见解相结合,可能会导致下一代微生物癌症治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Build-a-bug workshop: Using microbial-host interactions and synthetic biology tools to create cancer therapies.

Many systemically administered cancer therapies exhibit dose-limiting toxicities that reduce their effectiveness. To increase efficacy, bacterial delivery platforms have been developed that improve safety and prolong treatment. Bacteria are a unique class of therapy that selectively colonizes most solid tumors. As delivery vehicles, bacteria have been genetically modified to express a range of therapies that match multiple cancer indications. In this review, we describe a modular "build-a-bug" method that focuses on five design characteristics: bacterial strain (chassis), therapeutic compound, delivery method, immune-modulating features, and genetic control circuits. We emphasize how fundamental research into gut microbe pathogenesis has created safe bacterial therapies, some of which have entered clinical trials. The genomes of gut microbes are fertile grounds for discovery of components to improve delivery and modulate host immune responses. Future work coupling these delivery vehicles with insights from gut microbes could lead to the next generation of microbial cancer therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
From poo to promise: Fecal microbiota transplants support immunotherapy re-sensitization in solid tumors. Human cytomegalovirus degrades DMXL1 to inhibit autophagy, lysosomal acidification, and viral assembly. A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy. Cytoplasmic calcium influx mediated by plant MLKLs confers TNL-triggered immunity. Opposing diet, microbiome, and metabolite mechanisms regulate inflammatory bowel disease in a genetically susceptible host.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1